Phase II Study of Pemigatinib in Patients With Adenosquamous Carcinoma of the Pancreas
The purpose of this phase II study is to evaluate the safety and efficacy of pemigatinib in patients with advanced or surgically unresectable adenosquamous carcinoma of the pancreas who have progressed on previous therapy.
Study ID: Incyte-54828-19-05
Trial Phase: Phase II
Trial Sponsor: HonorHealth Research Institute
Therapies Used in This Trial: Pemigatinib